1、Breakthroughs that change patients lives January 31,2023Fourth Quarter 2022 Earnings TeleconferenceIntroductionChristopher StevoSenior Vice President,Chief Investor Relations Officer3Fourth Quarter 2022 EarningsForward-Looking Statements and Non-GAAP Financial InformationOur discussions during this

2、conference call will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.We include forward-looking statements about,among other topics,our anticipated opera

3、ting and financial performance;reorganizations;business plans,strategy and prospects;our Environmental,Social and Governance(ESG)priorities,strategy and goals;expectations for our product pipeline,in-line products and product candidates,including anticipated regulatory submissions,data read-outs,stu

4、dy starts,approvals,launches,clinical trial results and other developing data,revenue contribution and projections,pricing and reimbursement,potential market dynamics and size,growth,performance,timing of exclusivity and potential benefits;strategic reviews,capital allocation objectives,dividends an

5、d share repurchases;plans for and prospects of our acquisitions,dispositions and other business development activities;and our ability to successfully capitalize on these opportunities;manufacturing and product supply;our efforts to respond to COVID-19,including the Pfizer-BioNTech COVID-19 Vaccine(

6、Comirnaty),the Pfizer-BioNTech COVID-19 Omicron BA.4/BA.5-adapted bivalent Vaccine(the Pfizer-BioNTech COVID-19 bivalent vaccine),other vaccines that may result from the BNT162 program,and our oral COVID-19 treatment(Paxlovid);and our expectations regarding the impact of COVID-19 on our business,ope